Every year, 2.5 million patients can recover thanks to Polish researchers. Łukasiewicz – The Institute of Industrial Chemistry in Warsaw develops and produces active substances (APIs) that become the “heart” of medicines that restore the health of patients worldwide. In 2024 alone, the Institute produced 253,297,450 doses.
Every gram of APIs represents thousands of doses of medicine, and every produced kilogram stands for the health of millions of patients. In 2024 alone, Łukasiewicz – IChP produced 253,297,450 doses of active substances (APIs – Active Pharmaceutical Ingredients).
APIs are not a drug – they stand for life in a pill! Assuming that we consider the most common indication, the lowest therapeutic dose, and the shortest effective treatment time, the 250 million doses we have produced means real help for as many as 2,464,521 patients. If we lined them up, they could hold hands and create a route longer than the Great Wall of China.
Polish APIs – Europe’s health security
Despite the possessed competence, mastery of advanced technology, and research facilities, today more than 80% of the active substances used in Europe come from Asian countries. The COVID-19 pandemic was a brutal reminder to the world about the dangers of this dependency. Supply disruptions can be caused not only by global health crises, but also by climate change or geopolitical conflicts, which can lead to dramatic shortages, even of basic medicines in pharmacies.
Poland has over 70 years of experience in API production
The answer to these challenges consists in investing in production independence. Łukasiewicz – IChP, as the heir to the Pharmaceutical Institute, has been producing active substances for decades. In 2024, it began the construction of the state-of-the-art laboratories of the Mościcki Campus, an investment of PLN 240 million. Funding from European Funds (PLN 160 million from the National Programme for Reconstruction and Enhancement of Immunity) will allow the construction of three unique research and development centres, one of which will be strictly dedicated to the development and manufacture of active substances. This is a strategic boost to strengthen the national pharmaceutical potential and develop the production capacity of the Polish Institute.
Domestic production of active ingredients is more than chemistry - it is an investment in our security and sovereignty. Our APIs are not just molecules, but hope for patients, their families. Every gram that leaves our institute constitutes a response to the needs of millions of people around the world.
Łukasiewicz active substances – IChP worldwide
Products from Lukasiewicz – IChP have certifications in more than 60 countries, including Japan, where market approval standards are among the most demanding in the world. Researchers at the Polish Institute are constantly working on the synthesis of further molecules that could revolutionise pharmacy in the future, becoming the foundation for the development of new therapies or following drugs.
Łukasiewicz – IChP is a certified manufacturer of a number of GMP and CEP-certified active substances. There are 10 APIs in continuous production and a further 10 APIs are ready to be put into production. In addition, the Institute has 19 new API molecules to be commercialised.
